Literature DB >> 29930001

STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia.

Emmelie Cansby1, Elin Magnusson1, Esther Nuñez-Durán1, Manoj Amrutkar2, Matteo Pedrelli3, Paolo Parini3,4, Jenny Hoffmann1, Marcus Ståhlman5, Brian W Howell6, Hanns-Ulrich Marschall5, Jan Borén5, Margit Mahlapuu1.   

Abstract

Objective- Recent cohort studies have shown that nonalcoholic fatty liver disease (NAFLD), and especially nonalcoholic steatohepatitis (NASH), associate with atherosclerosis and cardiovascular disease, independently of conventional cardiometabolic risk factors. However, the mechanisms underlying the pathophysiological link between NAFLD/NASH and cardiovascular disease still remain unclear. Our previous studies have identified STK25 (serine/threonine protein kinase 25) as a critical determinant in ectopic lipid storage, meta-inflammation, and progression of NAFLD/NASH. The aim of this study was to assess whether STK25 is also one of the mediators in the complex molecular network controlling the cardiovascular disease risk. Approach and Results- Atherosclerosis was induced in Stk25 knockout and transgenic mice, and their wild-type littermates, by gene transfer of gain-of-function mutant of PCSK9 (proprotein convertase subtilisin/kexin type 9), which induces the downregulation of hepatic LDLR (low-density lipoprotein receptor), combined with an atherogenic western-type diet. We found that Stk25-/- mice displayed reduced atherosclerosis lesion area as well as decreased lipid accumulation, macrophage infiltration, collagen formation, and oxidative stress in aortic lesions compared with wild-type littermates, independently from alterations in dyslipidemia. Reciprocally, Stk25 transgenic mice presented aggravated plaque formation and maturation compared with wild-type littermates despite similar levels of fasting plasma cholesterol. We also found that STK25 protein was expressed in all layers of the aorta, suggesting a possible direct role in cardiovascular disease. Conclusions- This study provides the first evidence that STK25 plays a critical role in regulation of cardiovascular disease risk and suggests that pharmacological inhibition of STK25 function may provide new possibilities for prevention/treatment of atherosclerosis.

Entities:  

Keywords:  atherosclerosis; cholesterol; fibrosis; inflammation; liver

Mesh:

Substances:

Year:  2018        PMID: 29930001     DOI: 10.1161/ATVBAHA.118.311241

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

1.  Updates on Approaches for Studying Atherosclerosis.

Authors:  Congqing Wu; Alan Daugherty; Hong S Lu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

Review 2.  Annual Report on Sex in Preclinical Studies: Arteriosclerosis, Thrombosis, and Vascular Biology Publications in 2018.

Authors:  Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-12-23       Impact factor: 8.311

3.  Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.

Authors:  Emmelie Cansby; Esther Nuñez-Durán; Elin Magnusson; Manoj Amrutkar; Sheri L Booten; Nagaraj M Kulkarni; L Thomas Svensson; Jan Borén; Hanns-Ulrich Marschall; Mariam Aghajan; Margit Mahlapuu
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-12-19

4.  Depletion of protein kinase STK25 ameliorates renal lipotoxicity and protects against diabetic kidney disease.

Authors:  Emmelie Cansby; Mara Caputo; Lei Gao; Nagaraj M Kulkarni; Annika Nerstedt; Marcus Ståhlman; Jan Borén; Rando Porosk; Ursel Soomets; Matteo Pedrelli; Paolo Parini; Hanns-Ulrich Marschall; Jenny Nyström; Brian W Howell; Margit Mahlapuu
Journal:  JCI Insight       Date:  2020-12-17

5.  Silencing of STE20-type kinase STK25 in human aortic endothelial and smooth muscle cells is atheroprotective.

Authors:  Emmelie Cansby; Sima Kumari; Mara Caputo; Ying Xia; Rando Porosk; Jonathan Robinson; Hao Wang; Britt-Marie Olsson; Josefine Vallin; Julie Grantham; Ursel Soomets; L Thomas Svensson; Carina Sihlbom; Hanns-Ulrich Marschall; Andreas Edsfeldt; Isabel Goncalves; Margit Mahlapuu
Journal:  Commun Biol       Date:  2022-04-19

6.  STK25 inhibits PKA signaling by phosphorylating PRKAR1A.

Authors:  Xiaokan Zhang; Bryan Z Wang; Michael Kim; Trevor R Nash; Bohao Liu; Jenny Rao; Roberta Lock; Manuel Tamargo; Rajesh Kumar Soni; John Belov; Eric Li; Gordana Vunjak-Novakovic; Barry Fine
Journal:  Cell Rep       Date:  2022-08-16       Impact factor: 9.995

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.